SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP)
An SI Board Since March 1998
Posts SubjectMarks Bans Symbol
626 17 0 TTP
Emcee:  Arthur Radley Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
276 < They entitle the holder to purchase one share of common stock at an exercLLCF-1/23/1999
275 The following is from the last annual report. Jason WARRANTS At Decetnsaf-1/23/1999
274 <The warrants can be called if the stock price is above a certain level forLLCF-1/22/1999
273 <Hmmm, maybe I need one of those memory enhancing drugs.> Can I recommeLLCF-1/22/1999
272 The warrants can be called if the stock price is above a certain level for a sptnsaf-1/22/1999
271 Thanks for the correction regarding the location of trial sites. I re-read theJohn Metcalf-1/21/1999
270 Dr. Tracy: Thanks for the numbers re. piv phase II. Big difference, and imporscaram(o)uche-1/21/1999
269 <By my calculations the warrants are currently worth around $1 each (assumiLLCF-1/21/1999
268 I do not believe that it is correct to assume that only this 600pt study will bNeuroInvestment-1/21/1999
267 Hi NI: Welcome and hope You will continue to contribute on this and other SI tMiljenko Zuanic-1/21/1999
266 The information about Iloperidone's phase III trial has been known officialLel H-1/21/1999
265 "no real news has emerged other than Novartis reaffirming what was alreadyJohn Metcalf-1/20/1999
264 Rick: MZ and I have a long history of not seeing things similarly, so here is NeuroInvestment-1/20/1999
263 Same sort of sexy category. Just pointing out what an innovative approach to cscaram(o)uche-1/20/1999
262 Market setiment. Development stage biotechs under $100 m are avoided by funds Scott H. Davis-1/20/1999
261 <CFO confirmed that royalties for Iloperidone/Novartis will be 10% (of whatLLCF-1/20/1999
260 <oooops, posted some (?) relevant science to the old thread.....> So yoLLCF-1/20/1999
259 Rick, thanks for the reports. Seems like there are several potential applicatiScott H. Davis-1/20/1999
258 Nigel: This once was a Rosenthal/Aries/Paramount-like company. There is also scaram(o)uche-1/20/1999
257 Rick am I missing something ? I thought the Novartis announcement was extraornigel bates-1/20/1999
256 oooops, posted some (?) relevant science to the old thread...... exchange2000.scaram(o)uche-1/20/1999
255 <With the warrant exercise price close on double the current stock price anLLCF-1/20/1999
254 Take a look at ATRX this morning. It is trying to run. Arthur Radley-1/20/1999
253 I'm not quite as anxious as Rick - sometime in February would be fine ;) Scott H. Davis-1/20/1999
252 Peter, When I spoke with the CFO the stock was trading(much to my regret now)atArthur Radley-1/20/1999
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News